|
Tricyanoaminopropene
Tricyanoaminopropene (TRIAP, TCAP, Malononitrile Dimer, 1,1,3-tricyano-2-amino-1-propene) is a nootropic drug which mimics the function of nerve growth factor and increases the growth of nerves and tissue regeneration both in isolated tissues and ''in vivo''. It stimulates the action of the enzyme choline acetyltransferase, resulting in increased acetylcholine production. This then results in increased synthesis of RNA in many different tissues in the body. However it also suppresses the production of thyroxine, causing temporary hypothyroidism which returns to normal once the drug is discontinued. Tricyanoaminopropene reduces the amnesia produced by electroconvulsive shock, and animal tests suggested nootropic activity, but no beneficial effect was found when it was tested in mentally disabled children, and administration to pregnant rats actually reduced learning ability in their young because of its anti-thyroid hormone effects. This drug thus produces two effects which oppo ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Coluracetam
Coluracetam (INN; development code BCI-540; formerly MKC-231) is a purported nootropic agent of the racetam family. It is contains a chemical group that is a bioisostere of the 9-amino-tetrahydroacridine family. It was initially developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer's disease. After the drug failed to reach endpoints in its clinical trials it was in-licensed by BrainCells Inc for investigations into major depressive disorder (MDD), which was preceded by being awarded a "Qualifying Therapeutic Discovery Program Grant" by the state of California.phase IIa clinical trials have suggested that it would be a potential medication for comorbidity, comorbid MDD with generalized anxiety disorder (GAD).BrainCells Inc. ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |